Wave Life Sciences Q3 revenue, profit miss expectations

Wave Life Sciences

10/11/2025 12:39

Overview

Wave Life Sciences Q3 revenue and net income missed analyst expectations

Company maintains strong cash position, extending runway into Q2 2027

WVE-007 and WVE-006 clinical programs advance, achieving key objectives

Outlook

Wave expects multiple clinical data updates from INLIGHT trial in 2025 and 2026

Company plans to file NDA for WVE-N531 in 2026

Wave plans IND application for WVE-003 Phase 2/3 study in 2H 2025

Result Drivers

R&D - Expenses were $45.9 million in the third quarter of 2025 as compared to $41.2 million in the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$7.61 mln
$11.13 mln (15 Analysts)
Q3 EPS
-$0.32
Q3 Net Income
Miss
-$53.85 mln
-$49.55 mln (14 Analysts)
Q3 Income from Operations
Miss
-$56.35 mln
-$51.47 mln (14 Analysts)
Q3 Pretax Profit
Miss
-$53.85 mln
-$49.19 mln (13 Analysts)
Q3 Operating Expenses
$63.96 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for WAVE Life Sciences Ltd is $19.00, about 58.6% above its November 7 closing price of $7.86

Press Release: ID:nGNX9pl0nC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)